재조합 백신 시장 보고서(2026년)

Recombinant vaccines are immunizations produced using recombinant DNA technology, where selected genes coding for protective antigens from pathogens are introduced into safe host organisms to generate purified proteins that trigger targeted immune responses. These vaccines offer accurate, safe, and durable protection by activating immunity without exposing the body to the full pathogen, greatly lowering infection risks and side effects.

The primary types of recombinant vaccines comprise subunit vaccines and vector-based vaccines. Subunit vaccines are vaccines formulated with purified components of a pathogen, such as specific proteins, to trigger an immune response without incorporating live elements. These vaccines are developed for disease indications including human papillomavirus, herpes zoster, hepatitis B, and other diseases. They are administered through routes such as parenteral and other methods of administration and are intended for end users including pediatric and adult populations.

Tariffs on vaccine ingredients, bioprocess materials, and cold chain packaging are increasing production and distribution costs in the recombinant vaccines market. Import duties on adjuvants, culture media, and sterile vials are affecting subunit and vector vaccine segments. Regions dependent on cross border vaccine supply chains, particularly in developing economies, are seeing pricing and procurement challenges. Manufacturers are adjusting by regionalizing fill finish and packaging operations. Some governments are supporting local vaccine manufacturing to offset tariff effects. This is creating positive momentum for domestic vaccine facilities. It is also improving long term supply stability.

The recombinant vaccines market research report is one of a series of new reports from The Business Research Company that provides recombinant vaccines market statistics, including recombinant vaccines industry global market size, regional shares, competitors with a recombinant vaccines market share, detailed recombinant vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant vaccines industry. This recombinant vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The recombinant vaccines market size has grown rapidly in recent years. It will grow from $15.79 billion in 2025 to $17.69 billion in 2026 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to success of hepatitis B recombinant vaccines, historic global vaccination programs, rise in viral disease awareness, expansion of immunization funding, regulatory support for safer vaccine platforms.

The recombinant vaccines market size is expected to see rapid growth in the next few years. It will grow to $28.07 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to growing demand for precision vaccines, expansion of emerging disease vaccines, rising adult booster programs, increasing global immunization coverage, strong pipeline of recombinant candidates. Major trends in the forecast period include increase in recombinant subunit vaccines, expansion of vector based vaccine platforms, higher adult immunization programs, growth in combination recombinant vaccines, rising focus on long duration immunity.

The increasing prevalence of infectious diseases is expected to propel the growth of the recombinant vaccines market in the future. Infectious diseases are illnesses caused by microorganisms such as bacteria, viruses, fungi, or parasites that can spread from person to person directly or indirectly. The growing prevalence of infectious diseases is driven by poor sanitation and hygiene, as insufficient access to clean water, proper sanitation facilities, and effective waste management facilitates the spread of harmful microorganisms via contaminated food, water, and personal contact, increasing infection risk. Recombinant vaccines prevent infectious diseases by employing biologically engineered genetic material from pathogens to trigger an immune response without causing illness. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based national agency, over 109,000 chlamydia cases and more than 40,000 gonorrhea cases were reported as the most common sexually transmitted infections in Australia in 2023, along with over 6,400 infectious syphilis cases, highlighting the increasing prevalence and ongoing public health challenges. Therefore, the rising prevalence of infectious diseases is driving the recombinant vaccines market.

Key companies operating in the recombinant vaccines market are focusing on developing novel vaccines, such as the recombinant 9-valent HPV vaccine, to gain a competitive edge in the market. The recombinant 9-valent HPV vaccine is a vaccine that protects against nine types of human papillomavirus (HPV) and is made using recombinant DNA technology, which means it is produced in the laboratory without using live virus and helps prevent HPV-related diseases such as cervical cancer and genital warts. For example, in August 2023, Jiangsu Recbio Technology Co. Ltd., a China-based biopharmaceutical company, advanced REC603, its recombinant 9-valent HPV vaccine, through Phase III clinical follow-up with ongoing 24-month observations. The vaccine demonstrated strong immunogenicity, a favorable safety profile, scalable manufacturing potential, and long-term efficacy, supporting its potential for broad HPV prevention and commercialization.

In December 2025, Sanofi S.A., a France-based biopharmaceutical company, acquired Dynavax Technologies for an undisclosed amount. Through this acquisition, Sanofi intends to strengthen its adult immunization portfolio by integrating Dynavax's marketed HEPLISAV-B recombinant hepatitis B vaccine, its phase 1/2 shingles candidate, and other pipeline assets, enhancing global vaccine development, commercial reach, and innovation in recombinant vaccines. Dynavax Technologies Corporation is a US-based company that specializes in developing and commercializing recombinant vaccines for the prevention of infectious diseases, including hepatitis B and shingles.

Major companies operating in the recombinant vaccines market are Johnson And Johnson, Merck And Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca Plc, GlaxoSmithKline Plc, Mitsubishi Chemical Group Corporation, CSL Limited, Sinovac Biotech Ltd., Boehringer Ingelheim International GmbH, Zoetis Services Llc, Elanco Animal Health, BioNTech Se, Green Cross Corporation (Gc Biopharma), Bavarian Nordic A S, VBI Vaccines Inc., Vaxart Inc., Biological E Limited, Novavax Inc., Serum Institute Of India Private Limited, Vaxcyte Inc., Bharat Biotech International Limited, and Transgene S A.

North America was the largest region in the recombinant vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the recombinant vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The recombinant vaccines market consists of sales of recombinant hepatitis B vaccines, recombinant human papillomavirus vaccines, recombinant influenza vaccines, recombinant meningococcal vaccines, recombinant dengue vaccines, recombinant malaria vaccines, and recombinant shingles vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Recombinant Vaccines Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses recombinant vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for recombinant vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The recombinant vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Subunit Vaccines; Vector-Based Vaccines
• 2) By Disease Indication: Human Papillomavirus (HPV); Herpes Zoster; Hepatitis B; Other Diseases
• 3) By Route Of Administration: Parenteral; Other Route Of Administrations
• 4) By End User: Pediatric; Adults
• Subsegments:
• 1) By Subunit Vaccines: Protein Subunit Vaccines; Polysaccharide Subunit Vaccines; Conjugate Subunit Vaccines; Glycopeptide Subunit Vaccines; Recombinant Subunit Vaccines
• 2) By Vector-Based Vaccines: Viral Vector Vaccines; Non Viral Vector Vaccines; Replicating Vector Vaccines; Non Replicating Vector Vaccines; Bacterial Vector Vaccines
• Companies Mentioned: Johnson And Johnson; Merck And Co Inc.; Pfizer Inc.; Sanofi S. A.; Novartis AG; AstraZeneca Plc; GlaxoSmithKline Plc; Mitsubishi Chemical Group Corporation; CSL Limited; Sinovac Biotech Ltd.; Boehringer Ingelheim International GmbH; Zoetis Services Llc; Elanco Animal Health; BioNTech Se; Green Cross Corporation (Gc Biopharma); Bavarian Nordic A S; VBI Vaccines Inc.; Vaxart Inc.; Biological E Limited; Novavax Inc.; Serum Institute Of India Private Limited; Vaxcyte Inc.; Bharat Biotech International Limited; and Transgene S A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Recombinant Vaccines Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Recombinant Vaccines Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Recombinant Vaccines Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Recombinant Vaccines Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Sustainability, Climate Tech & Circular Economy
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Increase In Recombinant Subunit Vaccines
  • 4.2.2 Expansion Of Vector Based Vaccine Platforms
  • 4.2.3 Higher Adult Immunization Programs
  • 4.2.4 Growth In Combination Recombinant Vaccines
  • 4.2.5 Rising Focus On Long Duration Immunity

5. Recombinant Vaccines Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Vaccination Clinics
• 5.3 Public Health Agencies
• 5.4 Travel Health Centers
• 5.5 Community Health Centers

6. Recombinant Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Recombinant Vaccines Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Recombinant Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Recombinant Vaccines Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Recombinant Vaccines Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Recombinant Vaccines Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Recombinant Vaccines Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Recombinant Vaccines Market Segmentation

• 9.1. Global Recombinant Vaccines Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Subunit Vaccines, Vector-Based Vaccines
• 9.2. Global Recombinant Vaccines Market, Segmentation By Disease Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Human Papillomavirus (HPV), Herpes Zoster, Hepatitis B, Other Diseases
• 9.3. Global Recombinant Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Parenteral, Other Route Of Administrations
• 9.4. Global Recombinant Vaccines Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pediatric, Adults
• 9.5. Global Recombinant Vaccines Market, Sub-Segmentation Of Subunit Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines, Glycopeptide Subunit Vaccines, Recombinant Subunit Vaccines
• 9.6. Global Recombinant Vaccines Market, Sub-Segmentation Of Vector-Based Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Viral Vector Vaccines, Non Viral Vector Vaccines, Replicating Vector Vaccines, Non Replicating Vector Vaccines, Bacterial Vector Vaccines

10. Recombinant Vaccines Market Regional And Country Analysis

• 10.1. Global Recombinant Vaccines Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Recombinant Vaccines Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Recombinant Vaccines Market

• 11.1. Asia-Pacific Recombinant Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Recombinant Vaccines Market

• 12.1. China Recombinant Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Recombinant Vaccines Market

• 13.1. India Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Recombinant Vaccines Market

• 14.1. Japan Recombinant Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Recombinant Vaccines Market

• 15.1. Australia Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Recombinant Vaccines Market

• 16.1. Indonesia Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Recombinant Vaccines Market

• 17.1. South Korea Recombinant Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Recombinant Vaccines Market

• 18.1. Taiwan Recombinant Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Recombinant Vaccines Market

• 19.1. South East Asia Recombinant Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Recombinant Vaccines Market

• 20.1. Western Europe Recombinant Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Recombinant Vaccines Market

• 21.1. UK Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Recombinant Vaccines Market

• 22.1. Germany Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Recombinant Vaccines Market

• 23.1. France Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Recombinant Vaccines Market

• 24.1. Italy Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Recombinant Vaccines Market

• 25.1. Spain Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Recombinant Vaccines Market

• 26.1. Eastern Europe Recombinant Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Recombinant Vaccines Market

• 27.1. Russia Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Recombinant Vaccines Market

• 28.1. North America Recombinant Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Recombinant Vaccines Market

• 29.1. USA Recombinant Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Recombinant Vaccines Market

• 30.1. Canada Recombinant Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Recombinant Vaccines Market

• 31.1. South America Recombinant Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Recombinant Vaccines Market

• 32.1. Brazil Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Recombinant Vaccines Market

• 33.1. Middle East Recombinant Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Recombinant Vaccines Market

• 34.1. Africa Recombinant Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Recombinant Vaccines Market, Segmentation By Type, Segmentation By Disease Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Recombinant Vaccines Market Regulatory and Investment Landscape

36. Recombinant Vaccines Market Competitive Landscape And Company Profiles

• 36.1. Recombinant Vaccines Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Recombinant Vaccines Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Recombinant Vaccines Market Company Profiles
  • 36.3.1. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck And Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sanofi S. A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

37. Recombinant Vaccines Market Other Major And Innovative Companies

• AstraZeneca Plc, GlaxoSmithKline Plc, Mitsubishi Chemical Group Corporation, CSL Limited, Sinovac Biotech Ltd., Boehringer Ingelheim International GmbH, Zoetis Services Llc, Elanco Animal Health, BioNTech Se, Green Cross Corporation (Gc Biopharma), Bavarian Nordic A S, VBI Vaccines Inc., Vaxart Inc., Biological E Limited, Novavax Inc.

38. Global Recombinant Vaccines Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Recombinant Vaccines Market

41. Recombinant Vaccines Market High Potential Countries, Segments and Strategies

• 41.1 Recombinant Vaccines Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Recombinant Vaccines Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Recombinant Vaccines Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer